nodes	percent_of_prediction	percent_of_DWPC	metapath
Ranolazine—Cytochrome P450 2D6 Inhibitors—Pazopanib—kidney cancer	0.297	0.388	CiPCiCtD
Ranolazine—Cytochrome P450 2D6 Inhibitors—Everolimus—kidney cancer	0.297	0.388	CiPCiCtD
Ranolazine—P-Glycoprotein Inhibitors—Everolimus—kidney cancer	0.171	0.223	CiPCiCtD
Ranolazine—CYP2D6—Temsirolimus—kidney cancer	0.0243	0.169	CbGbCtD
Ranolazine—CYP3A4—Everolimus—kidney cancer	0.0228	0.159	CbGbCtD
Ranolazine—CYP3A4—Temsirolimus—kidney cancer	0.0154	0.108	CbGbCtD
Ranolazine—CYP2D6—Pazopanib—kidney cancer	0.0127	0.0889	CbGbCtD
Ranolazine—CYP2D6—Erlotinib—kidney cancer	0.0091	0.0635	CbGbCtD
Ranolazine—CYP3A4—Pazopanib—kidney cancer	0.00811	0.0566	CbGbCtD
Ranolazine—CYP2D6—Sorafenib—kidney cancer	0.0074	0.0516	CbGbCtD
Ranolazine—CYP2D6—Vinblastine—kidney cancer	0.0073	0.051	CbGbCtD
Ranolazine—CYP3A4—Erlotinib—kidney cancer	0.00578	0.0404	CbGbCtD
Ranolazine—CYP3A4—Paclitaxel—kidney cancer	0.00529	0.0369	CbGbCtD
Ranolazine—CYP3A4—Sorafenib—kidney cancer	0.0047	0.0328	CbGbCtD
Ranolazine—CYP3A4—Vinblastine—kidney cancer	0.00464	0.0324	CbGbCtD
Ranolazine—CYP3A4—Vincristine—kidney cancer	0.00457	0.0319	CbGbCtD
Ranolazine—CYP2D6—Doxorubicin—kidney cancer	0.00449	0.0313	CbGbCtD
Ranolazine—CYP3A4—Sunitinib—kidney cancer	0.00381	0.0266	CbGbCtD
Ranolazine—CYP3A4—Doxorubicin—kidney cancer	0.00285	0.0199	CbGbCtD
Ranolazine—SCN9A—Interaction between L1 and Ankyrins—L1CAM—kidney cancer	0.0011	0.086	CbGpPWpGaD
Ranolazine—SCN9A—Interaction between L1 and Ankyrins—SPTBN4—kidney cancer	0.0011	0.086	CbGpPWpGaD
Ranolazine—SCN5A—Interaction between L1 and Ankyrins—L1CAM—kidney cancer	0.000683	0.0535	CbGpPWpGaD
Ranolazine—SCN5A—Interaction between L1 and Ankyrins—SPTBN4—kidney cancer	0.000683	0.0535	CbGpPWpGaD
Ranolazine—Carvedilol—HIF1A—kidney cancer	0.000614	0.467	CrCbGaD
Ranolazine—SCN9A—L1CAM interactions—L1CAM—kidney cancer	0.000421	0.033	CbGpPWpGaD
Ranolazine—SCN9A—L1CAM interactions—SPTBN4—kidney cancer	0.000421	0.033	CbGpPWpGaD
Ranolazine—CYP3A4—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.000281	0.0221	CbGpPWpGaD
Ranolazine—CYP2D6—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.000271	0.0212	CbGpPWpGaD
Ranolazine—SCN5A—L1CAM interactions—L1CAM—kidney cancer	0.000262	0.0206	CbGpPWpGaD
Ranolazine—SCN5A—L1CAM interactions—SPTBN4—kidney cancer	0.000262	0.0206	CbGpPWpGaD
Ranolazine—Carvedilol—VEGFA—kidney cancer	0.000247	0.188	CrCbGaD
Ranolazine—SCN9A—Axon guidance—UNC5C—kidney cancer	0.00021	0.0165	CbGpPWpGaD
Ranolazine—SCN5A—Cardiac Progenitor Differentiation—PAX6—kidney cancer	0.000186	0.0146	CbGpPWpGaD
Ranolazine—CYP2D6—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000182	0.0142	CbGpPWpGaD
Ranolazine—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.000177	0.0139	CbGpPWpGaD
Ranolazine—SCN9A—L1CAM interactions—PAK1—kidney cancer	0.000161	0.0126	CbGpPWpGaD
Ranolazine—SCN9A—Axon guidance—L1CAM—kidney cancer	0.000159	0.0125	CbGpPWpGaD
Ranolazine—SCN9A—Axon guidance—SPTBN4—kidney cancer	0.000159	0.0125	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—UNC5C—kidney cancer	0.00015	0.0117	CbGpPWpGaD
Ranolazine—SCN5A—Cardiac Progenitor Differentiation—IGF2—kidney cancer	0.000132	0.0104	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—UNC5C—kidney cancer	0.000131	0.0102	CbGpPWpGaD
Ranolazine—Carvedilol—PTGS1—kidney cancer	0.000131	0.0994	CrCbGaD
Ranolazine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—kidney cancer	0.000128	0.0101	CbGpPWpGaD
Ranolazine—Carvedilol—CYP1A1—kidney cancer	0.000119	0.0909	CrCbGaD
Ranolazine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000119	0.00931	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—SPTBN4—kidney cancer	0.000113	0.0089	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—L1CAM—kidney cancer	0.000113	0.0089	CbGpPWpGaD
Ranolazine—CYP3A4—Irinotecan Pathway—BCHE—kidney cancer	0.000101	0.0079	CbGpPWpGaD
Ranolazine—SCN5A—Cardiac Progenitor Differentiation—KDR—kidney cancer	0.000101	0.00788	CbGpPWpGaD
Ranolazine—SCN5A—L1CAM interactions—PAK1—kidney cancer	0.0001	0.00788	CbGpPWpGaD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—HSPD1—kidney cancer	0.0001	0.00785	CbGpPWpGaD
Ranolazine—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—kidney cancer	9.95e-05	0.0078	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—CER1—kidney cancer	9.92e-05	0.00778	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—L1CAM—kidney cancer	9.91e-05	0.00777	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—SPTBN4—kidney cancer	9.91e-05	0.00777	CbGpPWpGaD
Ranolazine—CYP2D6—Melatonin metabolism and effects—ACHE—kidney cancer	9.88e-05	0.00775	CbGpPWpGaD
Ranolazine—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	9.6e-05	0.00753	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—UNC5C—kidney cancer	9.33e-05	0.00731	CbGpPWpGaD
Ranolazine—SCN5A—Cardiac Progenitor Differentiation—KIT—kidney cancer	9.26e-05	0.00726	CbGpPWpGaD
Ranolazine—Propranolol—CYP1A1—kidney cancer	9.08e-05	0.0691	CrCbGaD
Ranolazine—SCN9A—Developmental Biology—EPAS1—kidney cancer	8.97e-05	0.00703	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—HNF1A—kidney cancer	8.97e-05	0.00703	CbGpPWpGaD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—IL13—kidney cancer	8.41e-05	0.00659	CbGpPWpGaD
Ranolazine—CYP2D6—Xenobiotics—CYP1A1—kidney cancer	8.03e-05	0.0063	CbGpPWpGaD
Ranolazine—CYP2D6—Tamoxifen metabolism—CYP1A1—kidney cancer	7.72e-05	0.00606	CbGpPWpGaD
Ranolazine—CYP2D6—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	7.62e-05	0.00597	CbGpPWpGaD
Ranolazine—CYP3A4—Tryptophan metabolism—ALDH1A1—kidney cancer	7.6e-05	0.00596	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—ACY1—kidney cancer	7.39e-05	0.00579	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—HNF1B—kidney cancer	7.31e-05	0.00573	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—SPTBN4—kidney cancer	7.07e-05	0.00554	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—L1CAM—kidney cancer	7.07e-05	0.00554	CbGpPWpGaD
Ranolazine—Dizziness—Vinblastine—kidney cancer	6.96e-05	0.000904	CcSEcCtD
Ranolazine—Dizziness—Everolimus—kidney cancer	6.93e-05	0.000901	CcSEcCtD
Ranolazine—Muscle spasms—Paclitaxel—kidney cancer	6.93e-05	0.0009	CcSEcCtD
Ranolazine—Abdominal pain—Sunitinib—kidney cancer	6.92e-05	0.000899	CcSEcCtD
Ranolazine—Hypotension—Vincristine—kidney cancer	6.92e-05	0.000899	CcSEcCtD
Ranolazine—Bradycardia—Capecitabine—kidney cancer	6.92e-05	0.000899	CcSEcCtD
Ranolazine—Nervous system disorder—Gemcitabine—kidney cancer	6.89e-05	0.000895	CcSEcCtD
Ranolazine—Thrombocytopenia—Gemcitabine—kidney cancer	6.88e-05	0.000894	CcSEcCtD
Ranolazine—Renal failure acute—Doxorubicin—kidney cancer	6.86e-05	0.000891	CcSEcCtD
Ranolazine—Feeling abnormal—Dactinomycin—kidney cancer	6.83e-05	0.000887	CcSEcCtD
Ranolazine—Skin disorder—Gemcitabine—kidney cancer	6.82e-05	0.000887	CcSEcCtD
Ranolazine—Vision blurred—Paclitaxel—kidney cancer	6.79e-05	0.000882	CcSEcCtD
Ranolazine—Hyperhidrosis—Gemcitabine—kidney cancer	6.79e-05	0.000882	CcSEcCtD
Ranolazine—Gastrointestinal pain—Dactinomycin—kidney cancer	6.78e-05	0.000881	CcSEcCtD
Ranolazine—Hot flush—Doxorubicin—kidney cancer	6.77e-05	0.000879	CcSEcCtD
Ranolazine—Hypoaesthesia—Capecitabine—kidney cancer	6.76e-05	0.000878	CcSEcCtD
Ranolazine—Tremor—Paclitaxel—kidney cancer	6.75e-05	0.000877	CcSEcCtD
Ranolazine—Urinary tract disorder—Capecitabine—kidney cancer	6.71e-05	0.000872	CcSEcCtD
Ranolazine—Menopausal symptoms—Doxorubicin—kidney cancer	6.71e-05	0.000872	CcSEcCtD
Ranolazine—Insomnia—Vincristine—kidney cancer	6.7e-05	0.00087	CcSEcCtD
Ranolazine—Anorexia—Gemcitabine—kidney cancer	6.7e-05	0.00087	CcSEcCtD
Ranolazine—Oedema peripheral—Capecitabine—kidney cancer	6.69e-05	0.00087	CcSEcCtD
Ranolazine—Vomiting—Vinblastine—kidney cancer	6.69e-05	0.000869	CcSEcCtD
Ranolazine—Dizziness—Erlotinib—kidney cancer	6.69e-05	0.000869	CcSEcCtD
Ranolazine—Connective tissue disorder—Capecitabine—kidney cancer	6.68e-05	0.000867	CcSEcCtD
Ranolazine—Vomiting—Everolimus—kidney cancer	6.66e-05	0.000866	CcSEcCtD
Ranolazine—Urethral disorder—Capecitabine—kidney cancer	6.66e-05	0.000865	CcSEcCtD
Ranolazine—Paraesthesia—Vincristine—kidney cancer	6.65e-05	0.000864	CcSEcCtD
Ranolazine—Rash—Everolimus—kidney cancer	6.61e-05	0.000859	CcSEcCtD
Ranolazine—Dermatitis—Everolimus—kidney cancer	6.6e-05	0.000858	CcSEcCtD
Ranolazine—Headache—Vinblastine—kidney cancer	6.59e-05	0.000856	CcSEcCtD
Ranolazine—Angioedema—Paclitaxel—kidney cancer	6.58e-05	0.000856	CcSEcCtD
Ranolazine—Headache—Everolimus—kidney cancer	6.57e-05	0.000853	CcSEcCtD
Ranolazine—Hypotension—Gemcitabine—kidney cancer	6.56e-05	0.000853	CcSEcCtD
Ranolazine—Abdominal pain—Dactinomycin—kidney cancer	6.55e-05	0.000851	CcSEcCtD
Ranolazine—Visual impairment—Capecitabine—kidney cancer	6.55e-05	0.000851	CcSEcCtD
Ranolazine—Asthenia—Sorafenib—kidney cancer	6.53e-05	0.000848	CcSEcCtD
Ranolazine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	6.5e-05	0.00509	CbGpPWpGaD
Ranolazine—Vertigo—Paclitaxel—kidney cancer	6.47e-05	0.000841	CcSEcCtD
Ranolazine—Syncope—Paclitaxel—kidney cancer	6.46e-05	0.00084	CcSEcCtD
Ranolazine—Lethargy—Doxorubicin—kidney cancer	6.46e-05	0.000839	CcSEcCtD
Ranolazine—Leukopenia—Paclitaxel—kidney cancer	6.45e-05	0.000838	CcSEcCtD
Ranolazine—Decreased appetite—Vincristine—kidney cancer	6.44e-05	0.000836	CcSEcCtD
Ranolazine—Pruritus—Sorafenib—kidney cancer	6.44e-05	0.000836	CcSEcCtD
Ranolazine—Vomiting—Erlotinib—kidney cancer	6.43e-05	0.000835	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Vincristine—kidney cancer	6.39e-05	0.000831	CcSEcCtD
Ranolazine—Fatigue—Vincristine—kidney cancer	6.38e-05	0.00083	CcSEcCtD
Ranolazine—Rash—Erlotinib—kidney cancer	6.38e-05	0.000829	CcSEcCtD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—EGR1—kidney cancer	6.37e-05	0.005	CbGpPWpGaD
Ranolazine—Dermatitis—Erlotinib—kidney cancer	6.37e-05	0.000828	CcSEcCtD
Ranolazine—Palpitations—Paclitaxel—kidney cancer	6.37e-05	0.000827	CcSEcCtD
Ranolazine—Insomnia—Gemcitabine—kidney cancer	6.35e-05	0.000826	CcSEcCtD
Ranolazine—Eye disorder—Capecitabine—kidney cancer	6.35e-05	0.000825	CcSEcCtD
Ranolazine—Carvedilol—ABCB1—kidney cancer	6.35e-05	0.0483	CrCbGaD
Ranolazine—Headache—Erlotinib—kidney cancer	6.34e-05	0.000823	CcSEcCtD
Ranolazine—Tinnitus—Capecitabine—kidney cancer	6.33e-05	0.000823	CcSEcCtD
Ranolazine—Loss of consciousness—Paclitaxel—kidney cancer	6.33e-05	0.000823	CcSEcCtD
Ranolazine—Constipation—Vincristine—kidney cancer	6.33e-05	0.000823	CcSEcCtD
Ranolazine—Pain in extremity—Doxorubicin—kidney cancer	6.33e-05	0.000822	CcSEcCtD
Ranolazine—Diplopia—Doxorubicin—kidney cancer	6.33e-05	0.000822	CcSEcCtD
Ranolazine—Paraesthesia—Gemcitabine—kidney cancer	6.31e-05	0.00082	CcSEcCtD
Ranolazine—Cardiac disorder—Capecitabine—kidney cancer	6.3e-05	0.000819	CcSEcCtD
Ranolazine—Cough—Paclitaxel—kidney cancer	6.29e-05	0.000817	CcSEcCtD
Ranolazine—Asthenia—Sunitinib—kidney cancer	6.28e-05	0.000816	CcSEcCtD
Ranolazine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	6.28e-05	0.00492	CbGpPWpGaD
Ranolazine—Dyspnoea—Gemcitabine—kidney cancer	6.26e-05	0.000814	CcSEcCtD
Ranolazine—Nausea—Vinblastine—kidney cancer	6.25e-05	0.000812	CcSEcCtD
Ranolazine—Somnolence—Gemcitabine—kidney cancer	6.24e-05	0.000811	CcSEcCtD
Ranolazine—Nausea—Everolimus—kidney cancer	6.23e-05	0.000809	CcSEcCtD
Ranolazine—Pruritus—Sunitinib—kidney cancer	6.19e-05	0.000805	CcSEcCtD
Ranolazine—SCN5A—Developmental Biology—CER1—kidney cancer	6.18e-05	0.00484	CbGpPWpGaD
Ranolazine—Angiopathy—Capecitabine—kidney cancer	6.16e-05	0.000801	CcSEcCtD
Ranolazine—Mediastinal disorder—Capecitabine—kidney cancer	6.12e-05	0.000796	CcSEcCtD
Ranolazine—Anxiety—Paclitaxel—kidney cancer	6.11e-05	0.000794	CcSEcCtD
Ranolazine—Decreased appetite—Gemcitabine—kidney cancer	6.11e-05	0.000793	CcSEcCtD
Ranolazine—SCN9A—Axon guidance—PAK1—kidney cancer	6.09e-05	0.00478	CbGpPWpGaD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	6.09e-05	0.000792	CcSEcCtD
Ranolazine—Arrhythmia—Capecitabine—kidney cancer	6.07e-05	0.000789	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Gemcitabine—kidney cancer	6.06e-05	0.000788	CcSEcCtD
Ranolazine—Fatigue—Gemcitabine—kidney cancer	6.06e-05	0.000787	CcSEcCtD
Ranolazine—Gastrointestinal pain—Vincristine—kidney cancer	6.05e-05	0.000787	CcSEcCtD
Ranolazine—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	6.03e-05	0.00472	CbGpPWpGaD
Ranolazine—Dizziness—Sorafenib—kidney cancer	6.02e-05	0.000782	CcSEcCtD
Ranolazine—Constipation—Gemcitabine—kidney cancer	6.01e-05	0.000781	CcSEcCtD
Ranolazine—Nausea—Erlotinib—kidney cancer	6.01e-05	0.000781	CcSEcCtD
Ranolazine—Dry mouth—Paclitaxel—kidney cancer	6e-05	0.00078	CcSEcCtD
Ranolazine—CYP2D6—Melatonin metabolism and effects—CYP1A1—kidney cancer	5.97e-05	0.00468	CbGpPWpGaD
Ranolazine—Mental disorder—Capecitabine—kidney cancer	5.95e-05	0.000773	CcSEcCtD
Ranolazine—Asthenia—Dactinomycin—kidney cancer	5.95e-05	0.000773	CcSEcCtD
Ranolazine—Confusional state—Paclitaxel—kidney cancer	5.93e-05	0.000771	CcSEcCtD
Ranolazine—Blood creatinine increased—Doxorubicin—kidney cancer	5.93e-05	0.000771	CcSEcCtD
Ranolazine—Malnutrition—Capecitabine—kidney cancer	5.91e-05	0.000768	CcSEcCtD
Ranolazine—Dehydration—Doxorubicin—kidney cancer	5.89e-05	0.000765	CcSEcCtD
Ranolazine—Abdominal pain—Vincristine—kidney cancer	5.85e-05	0.000761	CcSEcCtD
Ranolazine—Flatulence—Capecitabine—kidney cancer	5.83e-05	0.000757	CcSEcCtD
Ranolazine—Dizziness—Sunitinib—kidney cancer	5.79e-05	0.000752	CcSEcCtD
Ranolazine—Feeling abnormal—Gemcitabine—kidney cancer	5.79e-05	0.000752	CcSEcCtD
Ranolazine—Shock—Paclitaxel—kidney cancer	5.79e-05	0.000752	CcSEcCtD
Ranolazine—Vomiting—Sorafenib—kidney cancer	5.78e-05	0.000752	CcSEcCtD
Ranolazine—Orthostatic hypotension—Doxorubicin—kidney cancer	5.78e-05	0.000751	CcSEcCtD
Ranolazine—Nervous system disorder—Paclitaxel—kidney cancer	5.77e-05	0.000749	CcSEcCtD
Ranolazine—Thrombocytopenia—Paclitaxel—kidney cancer	5.76e-05	0.000748	CcSEcCtD
Ranolazine—Rash—Sorafenib—kidney cancer	5.74e-05	0.000745	CcSEcCtD
Ranolazine—Dermatitis—Sorafenib—kidney cancer	5.73e-05	0.000745	CcSEcCtD
Ranolazine—Breast disorder—Doxorubicin—kidney cancer	5.72e-05	0.000743	CcSEcCtD
Ranolazine—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	5.71e-05	0.00448	CbGpPWpGaD
Ranolazine—Skin disorder—Paclitaxel—kidney cancer	5.71e-05	0.000742	CcSEcCtD
Ranolazine—Headache—Sorafenib—kidney cancer	5.7e-05	0.000741	CcSEcCtD
Ranolazine—Muscle spasms—Capecitabine—kidney cancer	5.69e-05	0.000739	CcSEcCtD
Ranolazine—Hyperhidrosis—Paclitaxel—kidney cancer	5.69e-05	0.000739	CcSEcCtD
Ranolazine—Anorexia—Paclitaxel—kidney cancer	5.61e-05	0.000728	CcSEcCtD
Ranolazine—SCN5A—Developmental Biology—EPAS1—kidney cancer	5.59e-05	0.00438	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—HNF1A—kidney cancer	5.59e-05	0.00438	CbGpPWpGaD
Ranolazine—Vision blurred—Capecitabine—kidney cancer	5.57e-05	0.000724	CcSEcCtD
Ranolazine—Vomiting—Sunitinib—kidney cancer	5.57e-05	0.000723	CcSEcCtD
Ranolazine—Tremor—Capecitabine—kidney cancer	5.54e-05	0.00072	CcSEcCtD
Ranolazine—Rash—Sunitinib—kidney cancer	5.52e-05	0.000717	CcSEcCtD
Ranolazine—Dermatitis—Sunitinib—kidney cancer	5.51e-05	0.000717	CcSEcCtD
Ranolazine—Hypotension—Paclitaxel—kidney cancer	5.5e-05	0.000714	CcSEcCtD
Ranolazine—Headache—Sunitinib—kidney cancer	5.48e-05	0.000713	CcSEcCtD
Ranolazine—CYP3A4—Irinotecan Pathway—APC—kidney cancer	5.47e-05	0.00429	CbGpPWpGaD
Ranolazine—Eosinophilia—Doxorubicin—kidney cancer	5.42e-05	0.000704	CcSEcCtD
Ranolazine—Nausea—Sorafenib—kidney cancer	5.4e-05	0.000702	CcSEcCtD
Ranolazine—Pancreatitis—Doxorubicin—kidney cancer	5.36e-05	0.000697	CcSEcCtD
Ranolazine—Insomnia—Paclitaxel—kidney cancer	5.32e-05	0.000691	CcSEcCtD
Ranolazine—Vertigo—Capecitabine—kidney cancer	5.31e-05	0.00069	CcSEcCtD
Ranolazine—Asthenia—Vincristine—kidney cancer	5.31e-05	0.00069	CcSEcCtD
Ranolazine—Syncope—Capecitabine—kidney cancer	5.3e-05	0.000689	CcSEcCtD
Ranolazine—Leukopenia—Capecitabine—kidney cancer	5.29e-05	0.000688	CcSEcCtD
Ranolazine—Paraesthesia—Paclitaxel—kidney cancer	5.28e-05	0.000686	CcSEcCtD
Ranolazine—Vomiting—Dactinomycin—kidney cancer	5.27e-05	0.000685	CcSEcCtD
Ranolazine—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	5.25e-05	0.00412	CbGpPWpGaD
Ranolazine—Dyspnoea—Paclitaxel—kidney cancer	5.24e-05	0.000681	CcSEcCtD
Ranolazine—SCN9A—Developmental Biology—CTNNA1—kidney cancer	5.24e-05	0.00411	CbGpPWpGaD
Ranolazine—SCN9A—L1CAM interactions—MAPK3—kidney cancer	5.23e-05	0.0041	CbGpPWpGaD
Ranolazine—Somnolence—Paclitaxel—kidney cancer	5.23e-05	0.000679	CcSEcCtD
Ranolazine—Palpitations—Capecitabine—kidney cancer	5.23e-05	0.000679	CcSEcCtD
Ranolazine—Rash—Dactinomycin—kidney cancer	5.23e-05	0.000679	CcSEcCtD
Ranolazine—Nausea—Sunitinib—kidney cancer	5.2e-05	0.000676	CcSEcCtD
Ranolazine—Loss of consciousness—Capecitabine—kidney cancer	5.2e-05	0.000675	CcSEcCtD
Ranolazine—Pancytopenia—Doxorubicin—kidney cancer	5.2e-05	0.000675	CcSEcCtD
Ranolazine—Dyspepsia—Paclitaxel—kidney cancer	5.18e-05	0.000673	CcSEcCtD
Ranolazine—Cough—Capecitabine—kidney cancer	5.16e-05	0.000671	CcSEcCtD
Ranolazine—Dysuria—Doxorubicin—kidney cancer	5.12e-05	0.000665	CcSEcCtD
Ranolazine—Decreased appetite—Paclitaxel—kidney cancer	5.11e-05	0.000664	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Paclitaxel—kidney cancer	5.08e-05	0.00066	CcSEcCtD
Ranolazine—Fatigue—Paclitaxel—kidney cancer	5.07e-05	0.000659	CcSEcCtD
Ranolazine—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	5.05e-05	0.00396	CbGpPWpGaD
Ranolazine—Asthenia—Gemcitabine—kidney cancer	5.04e-05	0.000655	CcSEcCtD
Ranolazine—Constipation—Paclitaxel—kidney cancer	5.03e-05	0.000653	CcSEcCtD
Ranolazine—Anxiety—Capecitabine—kidney cancer	5.02e-05	0.000652	CcSEcCtD
Ranolazine—SCN9A—Developmental Biology—PAX6—kidney cancer	5.02e-05	0.00393	CbGpPWpGaD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	5e-05	0.00065	CcSEcCtD
Ranolazine—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	4.98e-05	0.00391	CbGpPWpGaD
Ranolazine—SCN9A—L1CAM interactions—MAPK1—kidney cancer	4.98e-05	0.0039	CbGpPWpGaD
Ranolazine—Pruritus—Gemcitabine—kidney cancer	4.97e-05	0.000646	CcSEcCtD
Ranolazine—Weight decreased—Doxorubicin—kidney cancer	4.95e-05	0.000643	CcSEcCtD
Ranolazine—Dry mouth—Capecitabine—kidney cancer	4.92e-05	0.00064	CcSEcCtD
Ranolazine—Nausea—Dactinomycin—kidney cancer	4.92e-05	0.00064	CcSEcCtD
Ranolazine—Dizziness—Vincristine—kidney cancer	4.9e-05	0.000636	CcSEcCtD
Ranolazine—Confusional state—Capecitabine—kidney cancer	4.87e-05	0.000632	CcSEcCtD
Ranolazine—Feeling abnormal—Paclitaxel—kidney cancer	4.85e-05	0.00063	CcSEcCtD
Ranolazine—CYP3A4—Biological oxidations—ACY1—kidney cancer	4.83e-05	0.00379	CbGpPWpGaD
Ranolazine—Propranolol—ABCB1—kidney cancer	4.83e-05	0.0367	CrCbGaD
Ranolazine—Gastrointestinal pain—Paclitaxel—kidney cancer	4.81e-05	0.000625	CcSEcCtD
Ranolazine—Renal failure—Doxorubicin—kidney cancer	4.79e-05	0.000623	CcSEcCtD
Ranolazine—Shock—Capecitabine—kidney cancer	4.75e-05	0.000617	CcSEcCtD
Ranolazine—Nervous system disorder—Capecitabine—kidney cancer	4.73e-05	0.000615	CcSEcCtD
Ranolazine—Thrombocytopenia—Capecitabine—kidney cancer	4.73e-05	0.000614	CcSEcCtD
Ranolazine—Vomiting—Vincristine—kidney cancer	4.71e-05	0.000612	CcSEcCtD
Ranolazine—Skin disorder—Capecitabine—kidney cancer	4.69e-05	0.000609	CcSEcCtD
Ranolazine—Urticaria—Paclitaxel—kidney cancer	4.67e-05	0.000607	CcSEcCtD
Ranolazine—Rash—Vincristine—kidney cancer	4.67e-05	0.000607	CcSEcCtD
Ranolazine—Hyperhidrosis—Capecitabine—kidney cancer	4.67e-05	0.000606	CcSEcCtD
Ranolazine—Dermatitis—Vincristine—kidney cancer	4.66e-05	0.000606	CcSEcCtD
Ranolazine—Haematuria—Doxorubicin—kidney cancer	4.65e-05	0.000604	CcSEcCtD
Ranolazine—Abdominal pain—Paclitaxel—kidney cancer	4.65e-05	0.000604	CcSEcCtD
Ranolazine—Headache—Vincristine—kidney cancer	4.64e-05	0.000603	CcSEcCtD
Ranolazine—Epistaxis—Doxorubicin—kidney cancer	4.6e-05	0.000598	CcSEcCtD
Ranolazine—Anorexia—Capecitabine—kidney cancer	4.6e-05	0.000598	CcSEcCtD
Ranolazine—SCN5A—Developmental Biology—HNF1B—kidney cancer	4.56e-05	0.00357	CbGpPWpGaD
Ranolazine—Hypotension—Capecitabine—kidney cancer	4.51e-05	0.000586	CcSEcCtD
Ranolazine—Vomiting—Gemcitabine—kidney cancer	4.47e-05	0.00058	CcSEcCtD
Ranolazine—Bradycardia—Doxorubicin—kidney cancer	4.46e-05	0.000579	CcSEcCtD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—HIF1A—kidney cancer	4.43e-05	0.00348	CbGpPWpGaD
Ranolazine—Rash—Gemcitabine—kidney cancer	4.43e-05	0.000575	CcSEcCtD
Ranolazine—Dermatitis—Gemcitabine—kidney cancer	4.42e-05	0.000575	CcSEcCtD
Ranolazine—Headache—Gemcitabine—kidney cancer	4.4e-05	0.000572	CcSEcCtD
Ranolazine—Nausea—Vincristine—kidney cancer	4.4e-05	0.000571	CcSEcCtD
Ranolazine—Insomnia—Capecitabine—kidney cancer	4.37e-05	0.000567	CcSEcCtD
Ranolazine—Hypoaesthesia—Doxorubicin—kidney cancer	4.36e-05	0.000566	CcSEcCtD
Ranolazine—SCN9A—Developmental Biology—PAK1—kidney cancer	4.35e-05	0.00341	CbGpPWpGaD
Ranolazine—Paraesthesia—Capecitabine—kidney cancer	4.33e-05	0.000563	CcSEcCtD
Ranolazine—Urinary tract disorder—Doxorubicin—kidney cancer	4.32e-05	0.000562	CcSEcCtD
Ranolazine—Oedema peripheral—Doxorubicin—kidney cancer	4.31e-05	0.000561	CcSEcCtD
Ranolazine—Connective tissue disorder—Doxorubicin—kidney cancer	4.3e-05	0.000559	CcSEcCtD
Ranolazine—Dyspnoea—Capecitabine—kidney cancer	4.3e-05	0.000559	CcSEcCtD
Ranolazine—Urethral disorder—Doxorubicin—kidney cancer	4.29e-05	0.000558	CcSEcCtD
Ranolazine—Dyspepsia—Capecitabine—kidney cancer	4.25e-05	0.000552	CcSEcCtD
Ranolazine—Visual impairment—Doxorubicin—kidney cancer	4.22e-05	0.000548	CcSEcCtD
Ranolazine—Asthenia—Paclitaxel—kidney cancer	4.22e-05	0.000548	CcSEcCtD
Ranolazine—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	4.2e-05	0.00329	CbGpPWpGaD
Ranolazine—Decreased appetite—Capecitabine—kidney cancer	4.2e-05	0.000545	CcSEcCtD
Ranolazine—Nausea—Gemcitabine—kidney cancer	4.17e-05	0.000542	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Capecitabine—kidney cancer	4.17e-05	0.000541	CcSEcCtD
Ranolazine—Fatigue—Capecitabine—kidney cancer	4.16e-05	0.000541	CcSEcCtD
Ranolazine—Pruritus—Paclitaxel—kidney cancer	4.16e-05	0.000541	CcSEcCtD
Ranolazine—Constipation—Capecitabine—kidney cancer	4.13e-05	0.000536	CcSEcCtD
Ranolazine—Eye disorder—Doxorubicin—kidney cancer	4.09e-05	0.000532	CcSEcCtD
Ranolazine—Tinnitus—Doxorubicin—kidney cancer	4.08e-05	0.000531	CcSEcCtD
Ranolazine—Cardiac disorder—Doxorubicin—kidney cancer	4.06e-05	0.000528	CcSEcCtD
Ranolazine—CYP2D6—Biological oxidations—ALDH1A1—kidney cancer	4.05e-05	0.00317	CbGpPWpGaD
Ranolazine—Feeling abnormal—Capecitabine—kidney cancer	3.98e-05	0.000517	CcSEcCtD
Ranolazine—Angiopathy—Doxorubicin—kidney cancer	3.97e-05	0.000516	CcSEcCtD
Ranolazine—Gastrointestinal pain—Capecitabine—kidney cancer	3.95e-05	0.000513	CcSEcCtD
Ranolazine—Mediastinal disorder—Doxorubicin—kidney cancer	3.95e-05	0.000513	CcSEcCtD
Ranolazine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	3.92e-05	0.00307	CbGpPWpGaD
Ranolazine—Arrhythmia—Doxorubicin—kidney cancer	3.91e-05	0.000508	CcSEcCtD
Ranolazine—Dizziness—Paclitaxel—kidney cancer	3.89e-05	0.000505	CcSEcCtD
Ranolazine—Mental disorder—Doxorubicin—kidney cancer	3.84e-05	0.000498	CcSEcCtD
Ranolazine—Urticaria—Capecitabine—kidney cancer	3.83e-05	0.000498	CcSEcCtD
Ranolazine—Abdominal pain—Capecitabine—kidney cancer	3.82e-05	0.000496	CcSEcCtD
Ranolazine—Malnutrition—Doxorubicin—kidney cancer	3.81e-05	0.000495	CcSEcCtD
Ranolazine—SCN5A—Axon guidance—PAK1—kidney cancer	3.8e-05	0.00298	CbGpPWpGaD
Ranolazine—SCN9A—Axon guidance—KDR—kidney cancer	3.79e-05	0.00297	CbGpPWpGaD
Ranolazine—Flatulence—Doxorubicin—kidney cancer	3.76e-05	0.000488	CcSEcCtD
Ranolazine—Vomiting—Paclitaxel—kidney cancer	3.74e-05	0.000486	CcSEcCtD
Ranolazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	3.73e-05	0.00293	CbGpPWpGaD
Ranolazine—SCN9A—Axon guidance—MET—kidney cancer	3.71e-05	0.00291	CbGpPWpGaD
Ranolazine—Rash—Paclitaxel—kidney cancer	3.71e-05	0.000482	CcSEcCtD
Ranolazine—Dermatitis—Paclitaxel—kidney cancer	3.7e-05	0.000481	CcSEcCtD
Ranolazine—Headache—Paclitaxel—kidney cancer	3.68e-05	0.000479	CcSEcCtD
Ranolazine—Muscle spasms—Doxorubicin—kidney cancer	3.66e-05	0.000476	CcSEcCtD
Ranolazine—Vision blurred—Doxorubicin—kidney cancer	3.59e-05	0.000467	CcSEcCtD
Ranolazine—Nausea—Paclitaxel—kidney cancer	3.49e-05	0.000454	CcSEcCtD
Ranolazine—Asthenia—Capecitabine—kidney cancer	3.46e-05	0.00045	CcSEcCtD
Ranolazine—Vertigo—Doxorubicin—kidney cancer	3.42e-05	0.000445	CcSEcCtD
Ranolazine—Syncope—Doxorubicin—kidney cancer	3.42e-05	0.000444	CcSEcCtD
Ranolazine—Pruritus—Capecitabine—kidney cancer	3.41e-05	0.000444	CcSEcCtD
Ranolazine—Leukopenia—Doxorubicin—kidney cancer	3.41e-05	0.000443	CcSEcCtD
Ranolazine—Palpitations—Doxorubicin—kidney cancer	3.37e-05	0.000438	CcSEcCtD
Ranolazine—Loss of consciousness—Doxorubicin—kidney cancer	3.35e-05	0.000435	CcSEcCtD
Ranolazine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	3.34e-05	0.00261	CbGpPWpGaD
Ranolazine—Cough—Doxorubicin—kidney cancer	3.33e-05	0.000432	CcSEcCtD
Ranolazine—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	3.29e-05	0.00258	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—CTNNA1—kidney cancer	3.26e-05	0.00256	CbGpPWpGaD
Ranolazine—SCN5A—L1CAM interactions—MAPK3—kidney cancer	3.26e-05	0.00255	CbGpPWpGaD
Ranolazine—Anxiety—Doxorubicin—kidney cancer	3.23e-05	0.00042	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	3.22e-05	0.000419	CcSEcCtD
Ranolazine—Dizziness—Capecitabine—kidney cancer	3.19e-05	0.000415	CcSEcCtD
Ranolazine—Dry mouth—Doxorubicin—kidney cancer	3.17e-05	0.000412	CcSEcCtD
Ranolazine—Confusional state—Doxorubicin—kidney cancer	3.14e-05	0.000408	CcSEcCtD
Ranolazine—SCN5A—Developmental Biology—PAX6—kidney cancer	3.12e-05	0.00245	CbGpPWpGaD
Ranolazine—SCN5A—L1CAM interactions—MAPK1—kidney cancer	3.1e-05	0.00243	CbGpPWpGaD
Ranolazine—Vomiting—Capecitabine—kidney cancer	3.07e-05	0.000399	CcSEcCtD
Ranolazine—Shock—Doxorubicin—kidney cancer	3.06e-05	0.000398	CcSEcCtD
Ranolazine—Nervous system disorder—Doxorubicin—kidney cancer	3.05e-05	0.000396	CcSEcCtD
Ranolazine—Thrombocytopenia—Doxorubicin—kidney cancer	3.05e-05	0.000396	CcSEcCtD
Ranolazine—Rash—Capecitabine—kidney cancer	3.04e-05	0.000395	CcSEcCtD
Ranolazine—Dermatitis—Capecitabine—kidney cancer	3.04e-05	0.000395	CcSEcCtD
Ranolazine—Headache—Capecitabine—kidney cancer	3.02e-05	0.000393	CcSEcCtD
Ranolazine—Skin disorder—Doxorubicin—kidney cancer	3.02e-05	0.000393	CcSEcCtD
Ranolazine—Hyperhidrosis—Doxorubicin—kidney cancer	3.01e-05	0.000391	CcSEcCtD
Ranolazine—Anorexia—Doxorubicin—kidney cancer	2.97e-05	0.000385	CcSEcCtD
Ranolazine—Hypotension—Doxorubicin—kidney cancer	2.91e-05	0.000378	CcSEcCtD
Ranolazine—Nausea—Capecitabine—kidney cancer	2.87e-05	0.000372	CcSEcCtD
Ranolazine—Insomnia—Doxorubicin—kidney cancer	2.81e-05	0.000366	CcSEcCtD
Ranolazine—Paraesthesia—Doxorubicin—kidney cancer	2.79e-05	0.000363	CcSEcCtD
Ranolazine—Dyspnoea—Doxorubicin—kidney cancer	2.77e-05	0.00036	CcSEcCtD
Ranolazine—Somnolence—Doxorubicin—kidney cancer	2.77e-05	0.000359	CcSEcCtD
Ranolazine—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	2.74e-05	0.00215	CbGpPWpGaD
Ranolazine—SCN9A—Axon guidance—RAF1—kidney cancer	2.74e-05	0.00215	CbGpPWpGaD
Ranolazine—Dyspepsia—Doxorubicin—kidney cancer	2.74e-05	0.000356	CcSEcCtD
Ranolazine—SCN9A—Axon guidance—ERBB2—kidney cancer	2.71e-05	0.00213	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—PAK1—kidney cancer	2.71e-05	0.00212	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—KDR—kidney cancer	2.71e-05	0.00212	CbGpPWpGaD
Ranolazine—Decreased appetite—Doxorubicin—kidney cancer	2.7e-05	0.000351	CcSEcCtD
Ranolazine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	2.7e-05	0.00212	CbGpPWpGaD
Ranolazine—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	2.7e-05	0.00211	CbGpPWpGaD
Ranolazine—Gastrointestinal disorder—Doxorubicin—kidney cancer	2.69e-05	0.000349	CcSEcCtD
Ranolazine—Fatigue—Doxorubicin—kidney cancer	2.68e-05	0.000349	CcSEcCtD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—JUN—kidney cancer	2.67e-05	0.0021	CbGpPWpGaD
Ranolazine—Constipation—Doxorubicin—kidney cancer	2.66e-05	0.000346	CcSEcCtD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	2.65e-05	0.00208	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—MET—kidney cancer	2.65e-05	0.00208	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	2.65e-05	0.00207	CbGpPWpGaD
Ranolazine—Feeling abnormal—Doxorubicin—kidney cancer	2.56e-05	0.000333	CcSEcCtD
Ranolazine—Gastrointestinal pain—Doxorubicin—kidney cancer	2.54e-05	0.000331	CcSEcCtD
Ranolazine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	2.49e-05	0.00195	CbGpPWpGaD
Ranolazine—Urticaria—Doxorubicin—kidney cancer	2.47e-05	0.000321	CcSEcCtD
Ranolazine—Abdominal pain—Doxorubicin—kidney cancer	2.46e-05	0.00032	CcSEcCtD
Ranolazine—CYP2D6—Biological oxidations—GSTT1—kidney cancer	2.38e-05	0.00186	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—KDR—kidney cancer	2.36e-05	0.00185	CbGpPWpGaD
Ranolazine—SCN5A—SIDS Susceptibility Pathways—VEGFA—kidney cancer	2.34e-05	0.00183	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—MET—kidney cancer	2.31e-05	0.00181	CbGpPWpGaD
Ranolazine—Asthenia—Doxorubicin—kidney cancer	2.23e-05	0.00029	CcSEcCtD
Ranolazine—CYP2D6—Biological oxidations—PTGS1—kidney cancer	2.23e-05	0.00175	CbGpPWpGaD
Ranolazine—Pruritus—Doxorubicin—kidney cancer	2.2e-05	0.000286	CcSEcCtD
Ranolazine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	2.18e-05	0.00171	CbGpPWpGaD
Ranolazine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	2.15e-05	0.00169	CbGpPWpGaD
Ranolazine—SCN9A—Axon guidance—VEGFA—kidney cancer	2.09e-05	0.00164	CbGpPWpGaD
Ranolazine—Dizziness—Doxorubicin—kidney cancer	2.06e-05	0.000267	CcSEcCtD
Ranolazine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—kidney cancer	2.02e-05	0.00158	CbGpPWpGaD
Ranolazine—Vomiting—Doxorubicin—kidney cancer	1.98e-05	0.000257	CcSEcCtD
Ranolazine—SCN9A—Axon guidance—MAPK3—kidney cancer	1.98e-05	0.00155	CbGpPWpGaD
Ranolazine—Rash—Doxorubicin—kidney cancer	1.96e-05	0.000255	CcSEcCtD
Ranolazine—Dermatitis—Doxorubicin—kidney cancer	1.96e-05	0.000255	CcSEcCtD
Ranolazine—SCN9A—Developmental Biology—RAF1—kidney cancer	1.96e-05	0.00153	CbGpPWpGaD
Ranolazine—Headache—Doxorubicin—kidney cancer	1.95e-05	0.000253	CcSEcCtD
Ranolazine—SCN9A—Developmental Biology—RELA—kidney cancer	1.95e-05	0.00153	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—ERBB2—kidney cancer	1.94e-05	0.00152	CbGpPWpGaD
Ranolazine—SCN9A—Axon guidance—MAPK1—kidney cancer	1.88e-05	0.00147	CbGpPWpGaD
Ranolazine—Nausea—Doxorubicin—kidney cancer	1.85e-05	0.00024	CcSEcCtD
Ranolazine—SCN9A—Axon guidance—KRAS—kidney cancer	1.78e-05	0.00139	CbGpPWpGaD
Ranolazine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	1.77e-05	0.00139	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—RAF1—kidney cancer	1.71e-05	0.00134	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—CTNNB1—kidney cancer	1.69e-05	0.00133	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—ERBB2—kidney cancer	1.69e-05	0.00132	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—KDR—kidney cancer	1.69e-05	0.00132	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—MET—kidney cancer	1.65e-05	0.00129	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—GSTP1—kidney cancer	1.65e-05	0.00129	CbGpPWpGaD
Ranolazine—CYP2D6—Metapathway biotransformation—GSTP1—kidney cancer	1.63e-05	0.00127	CbGpPWpGaD
Ranolazine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	1.63e-05	0.00127	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—GSTT1—kidney cancer	1.56e-05	0.00122	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—GSTM1—kidney cancer	1.52e-05	0.00119	CbGpPWpGaD
Ranolazine—CYP2D6—Metapathway biotransformation—GSTM1—kidney cancer	1.49e-05	0.00117	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—VEGFA—kidney cancer	1.49e-05	0.00117	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—PTGS1—kidney cancer	1.46e-05	0.00114	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—CYP1A1—kidney cancer	1.44e-05	0.00113	CbGpPWpGaD
Ranolazine—CYP2D6—Metapathway biotransformation—CYP1A1—kidney cancer	1.42e-05	0.00111	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—MAPK3—kidney cancer	1.41e-05	0.00111	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—MAPK1—kidney cancer	1.34e-05	0.00105	CbGpPWpGaD
Ranolazine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	1.32e-05	0.00103	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—VEGFA—kidney cancer	1.3e-05	0.00102	CbGpPWpGaD
Ranolazine—SCN9A—Developmental Biology—KRAS—kidney cancer	1.27e-05	0.000994	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ACY1—kidney cancer	1.26e-05	0.00099	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—MAPK3—kidney cancer	1.23e-05	0.000965	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—RAF1—kidney cancer	1.22e-05	0.000956	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—RELA—kidney cancer	1.21e-05	0.000951	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—ERBB2—kidney cancer	1.21e-05	0.000945	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—MAPK1—kidney cancer	1.17e-05	0.000919	CbGpPWpGaD
Ranolazine—SCN5A—Axon guidance—KRAS—kidney cancer	1.11e-05	0.000868	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—GSTP1—kidney cancer	1.08e-05	0.000845	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PDHB—kidney cancer	1.07e-05	0.000842	CbGpPWpGaD
Ranolazine—CYP2D6—Biological oxidations—POMC—kidney cancer	1.07e-05	0.000839	CbGpPWpGaD
Ranolazine—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	1.06e-05	0.000833	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—CTNNB1—kidney cancer	1.06e-05	0.000827	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—CCBL1—kidney cancer	1.01e-05	0.000792	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—GSTM1—kidney cancer	9.91e-06	0.000777	CbGpPWpGaD
Ranolazine—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	9.77e-06	0.000766	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	9.39e-06	0.000736	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—VEGFA—kidney cancer	9.29e-06	0.000728	CbGpPWpGaD
Ranolazine—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	9.26e-06	0.000726	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—MAPK3—kidney cancer	8.79e-06	0.000689	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—GLIPR1—kidney cancer	8.76e-06	0.000686	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PPAT—kidney cancer	8.76e-06	0.000686	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—MAPK1—kidney cancer	8.36e-06	0.000655	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ACY1—kidney cancer	8.26e-06	0.000648	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—FH—kidney cancer	8.14e-06	0.000638	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—APRT—kidney cancer	8.14e-06	0.000638	CbGpPWpGaD
Ranolazine—SCN5A—Developmental Biology—KRAS—kidney cancer	7.9e-06	0.000619	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—GPC3—kidney cancer	7.65e-06	0.0006	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—CA2—kidney cancer	7.45e-06	0.000584	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ALAD—kidney cancer	7.26e-06	0.000569	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ST3GAL2—kidney cancer	7.08e-06	0.000555	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PDHB—kidney cancer	7.02e-06	0.000551	CbGpPWpGaD
Ranolazine—CYP3A4—Biological oxidations—POMC—kidney cancer	7e-06	0.000549	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ALDH1A1—kidney cancer	6.92e-06	0.000543	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PGK1—kidney cancer	6.64e-06	0.00052	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—SLC5A3—kidney cancer	6.64e-06	0.00052	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—CCBL1—kidney cancer	6.6e-06	0.000518	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—LDHB—kidney cancer	6.51e-06	0.00051	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PPAT—kidney cancer	5.73e-06	0.000449	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—GLIPR1—kidney cancer	5.73e-06	0.000449	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—CA9—kidney cancer	5.64e-06	0.000442	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—FH—kidney cancer	5.32e-06	0.000417	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—APRT—kidney cancer	5.32e-06	0.000417	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—GPC3—kidney cancer	5e-06	0.000392	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—CA2—kidney cancer	4.87e-06	0.000382	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—CRABP1—kidney cancer	4.8e-06	0.000376	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ALAD—kidney cancer	4.74e-06	0.000372	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ST3GAL2—kidney cancer	4.63e-06	0.000363	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ALDH1A1—kidney cancer	4.53e-06	0.000355	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ITPR2—kidney cancer	4.46e-06	0.00035	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—SLC5A3—kidney cancer	4.34e-06	0.00034	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PGK1—kidney cancer	4.34e-06	0.00034	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—LDHB—kidney cancer	4.25e-06	0.000334	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—GSTT1—kidney cancer	4.07e-06	0.000319	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ACHE—kidney cancer	4.07e-06	0.000319	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—SCARB1—kidney cancer	3.85e-06	0.000302	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PTGS1—kidney cancer	3.81e-06	0.000299	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PSMD7—kidney cancer	3.74e-06	0.000293	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—CA9—kidney cancer	3.69e-06	0.000289	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—BCHE—kidney cancer	3.54e-06	0.000278	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—SLC5A5—kidney cancer	3.5e-06	0.000274	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—SLC2A1—kidney cancer	3.38e-06	0.000265	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—CRABP1—kidney cancer	3.14e-06	0.000246	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ITPR2—kidney cancer	2.92e-06	0.000229	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—GSTP1—kidney cancer	2.82e-06	0.000221	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—ABCB1—kidney cancer	2.67e-06	0.000209	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—GSTT1—kidney cancer	2.66e-06	0.000208	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ACHE—kidney cancer	2.66e-06	0.000208	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—GSTM1—kidney cancer	2.59e-06	0.000203	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—SCARB1—kidney cancer	2.52e-06	0.000197	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PTGS1—kidney cancer	2.49e-06	0.000195	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—CYP1A1—kidney cancer	2.46e-06	0.000193	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PSMD7—kidney cancer	2.44e-06	0.000192	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—BCHE—kidney cancer	2.32e-06	0.000182	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—SLC5A5—kidney cancer	2.29e-06	0.000179	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—SLC2A1—kidney cancer	2.21e-06	0.000173	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—GSTP1—kidney cancer	1.84e-06	0.000145	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—POMC—kidney cancer	1.83e-06	0.000144	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—ABCB1—kidney cancer	1.74e-06	0.000137	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—GSTM1—kidney cancer	1.69e-06	0.000133	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—CYP1A1—kidney cancer	1.61e-06	0.000126	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PTGS2—kidney cancer	1.46e-06	0.000115	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PTEN—kidney cancer	1.27e-06	9.99e-05	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—POMC—kidney cancer	1.2e-06	9.39e-05	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PTGS2—kidney cancer	9.55e-07	7.49e-05	CbGpPWpGaD
Ranolazine—CYP2D6—Metabolism—PIK3CA—kidney cancer	8.99e-07	7.04e-05	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PTEN—kidney cancer	8.33e-07	6.53e-05	CbGpPWpGaD
Ranolazine—CYP3A4—Metabolism—PIK3CA—kidney cancer	5.88e-07	4.61e-05	CbGpPWpGaD
